Literature DB >> 27865392

Mycobacterium indicus pranii (MIP) mediated host protective intracellular mechanisms against tuberculosis infection: Involvement of TLR-4 mediated signaling.

Shibali Das1, Bidisha Paul Chowdhury1, Avranil Goswami2, Shabina Parveen1, Junaid Jawed1, Nishith Pal3, Subrata Majumdar4.   

Abstract

Mycobacterium tuberculosis infection inflicts the disease Tuberculosis (TB), which is fatal if left untreated. During M. tuberculosis infection, the pathogen modulates TLR-4 receptor down-stream signaling, indicating the possible involvement of TLR-4 in the regulation of the host immune response. Mycobacterium indicus pranii (MIP) possesses immuno-modulatory properties which induces the pro-inflammatory responses via induction of TLR-4-mediated signaling. Here, we observed the immunomodulatory properties of MIP against tuberculosis infection. We have studied the detailed signaling mechanisms employed by MIP in order to restore the host immune response against the in vitro tuberculosis infection. We observed that in infected macrophages MIP treatment significantly increased the TLR-4 expression as well as activation of its downstream signaling, facilitating the activation of P38 MAP kinase. MIP treatment was able to activate NF-κB via involvement of TLR-4 signaling leading to the enhanced pro-inflammatory cytokine and NO generation in the infected macrophages and generation of protective immune response. Therefore, we may suggest that, TLR4 may represent a novel therapeutic target for the activation of the innate immune response during Tuberculosis infection.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Cytokine; MAP kinase; Mycobacterium indicus pranii; TLR-4; Tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 27865392     DOI: 10.1016/j.tube.2016.09.027

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  9 in total

Review 1.  The current status, challenges, and future developments of new tuberculosis vaccines.

Authors:  Wenping Gong; Yan Liang; Xueqiong Wu
Journal:  Hum Vaccin Immunother       Date:  2018-05-14       Impact factor: 3.452

Review 2.  Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.

Authors:  Lampouguin Yenkoidiok-Douti; Christopher M Jewell
Journal:  ACS Biomater Sci Eng       Date:  2020-01-12

Review 3.  Pulmonary non-tuberculous mycobacterial infections: current state and future management.

Authors:  Kai Ling Chin; Maria E Sarmiento; Nadine Alvarez-Cabrera; Mohd Nor Norazmi; Armando Acosta
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-18       Impact factor: 3.267

Review 4.  Modulation of Autophagy for Controlling Immunity.

Authors:  Young Jin Jang; Jae Hwan Kim; Sanguine Byun
Journal:  Cells       Date:  2019-02-09       Impact factor: 6.600

5.  Polyamine Transport Protein PotD Protects Mice against Haemophilus parasuis and Elevates the Secretion of Pro-Inflammatory Cytokines of Macrophage via JNK-MAPK and NF-κB Signal Pathways through TLR4.

Authors:  Ke Dai; Xiaoyu Ma; Zhen Yang; Yung-Fu Chang; Sanjie Cao; Qin Zhao; Xiaobo Huang; Rui Wu; Yong Huang; Qigui Yan; Xinfeng Han; Xiaoping Ma; Xintian Wen; Yiping Wen
Journal:  Vaccines (Basel)       Date:  2019-12-14

Review 6.  The Research Progress in Immunotherapy of Tuberculosis.

Authors:  Jie Mi; Yan Liang; Jianqin Liang; Wenping Gong; Shuyong Wang; Junxian Zhang; Zhiming Li; Xueqiong Wu
Journal:  Front Cell Infect Microbiol       Date:  2021-11-15       Impact factor: 5.293

Review 7.  It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity.

Authors:  Sasha E Larsen; Brittany D Williams; Maham Rais; Rhea N Coler; Susan L Baldwin
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

8.  Recombinant BCG expressing the LTAK63 adjuvant improves a short-term chemotherapy schedule in the control of tuberculosis in mice.

Authors:  Monalisa Martins Trentini; Alex Issamu Kanno; Dunia Rodriguez; Lazaro Moreira Marques-Neto; Silas Fernandes Eto; Ana Marisa Chudzinki-Tavassi; Luciana Cezar de Cerqueira Leite
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

Review 9.  Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis.

Authors:  Sam Afkhami; Anne Drumond Villela; Michael R D'Agostino; Mangalakumari Jeyanathan; Amy Gillgrass; Zhou Xing
Journal:  Front Immunol       Date:  2020-09-09       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.